Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease

Slides:

Advertisements

Similar presentations

A Hole in the Heart Journal of Thoracic Oncology

Advertisements

Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Erratum Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Yuen Yee Cheng, PhD, Michaela B

A Mass Spectrometry Assay to Simultaneously Analyze ROS1 and RET Fusion Gene Expression in Non–Small-Cell Lung Cancer Priyanga Wijesinghe, PhD, Gerold.

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer Xiaoxia Chen,

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Epithelial-Specific Methylation Marker: A Potential Plasma Biomarker in Advanced Non- small Cell Lung Cancer Chanida Vinayanuwattikun, MD, Virote Sriuranpong,

A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis María Uribarri, PhD, Itsaso Hormaeche, PhD, Rafael Zalacain, MD,

Kyong-Ah Yoon, Sohee Park, Sang Hee Lee, Jin Hee Kim, Jin Soo Lee

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Tumor Cell Content for Selection of Molecular Techniques for T790M EGFR Mutation Detection in Non-small Cell Lung Cancer Nathalie Prim, Elisabeth Quoix,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Reliability Assurance of Detection of EML4-ALK Rearrangement in Non–Small Cell Lung Cancer: The Results of Proficiency Testing in China Yulong Li, MD,

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Sai-Hong Ignatius Ou, MD, PhD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Liang Wang, MD, Jeremiah A. Aakre, BS, Ruoxiang Jiang, BS, Randolph S

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

CtDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study Martin Reck, MD, PhD, Koichi Hagiwara,

A Hole in the Heart Journal of Thoracic Oncology

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Erratum Journal of Thoracic Oncology

A Different Method in Diagnosis of Multiple Primary Lung Cancer

ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

A Primer on Health Economic Evaluations in Thoracic Oncology

Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma Alfonso Cristaudo, MD, Alessandra Bonotti, PhD, Silvia.

SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma Christoph Kneip, PhD, Bernd Schmidt, MD, Anke Seegebarth, Sabine Weickmann,

CT Features of Epidermal Growth Factor Receptor–Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma Mizue Hasegawa, MD, PhD,

Nivolumab-Induced Granulomatous Inflammation of the Pleura

MTP13-01: Indications and limitations of bronchoscopy

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

It’s All in the “Swerve of the Curve”

Internal validation of risk models in lung resection surgery: Bootstrap versus training- and-test sampling Alessandro Brunelli, MD, Gaetano Rocco, MD

Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma Zacariah E. Labby, PhD, Samuel G. Armato, PhD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

European Lung Cancer Conference (ELCC) 2016 Organisation

Non-invasive Breath Analysis of Pulmonary Nodules

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Epidemiology of Thymoma and Associated Malignancies

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Regression of Paraneoplastic Rash after Lung Cancer Chemotherapy

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

MiR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non- small Cell Lung Cancer Kristen M. Foss, BS, Chao Sima, PhD, Donatella Ugolini,

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease Gunter Weiss, PhD, Anne Schlegel, PhD, Denise Kottwitz, PhD, Thomas König, Reimo Tetzner, PhD Journal of Thoracic Oncology Volume 12, Issue 1, Pages 77-84 (January 2017) DOI: 10.1016/j.jtho.2016.08.123 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Sample disposition, study setup, and polymerase chain reaction (PCR) assay formats. Boxes in the bottom line indicate number of valid results, number of PCR replicates, and bisDNA input volume (in parenthesis) per PCR assay. For more details, see Materials and Methods section. ACTB, actin, beta gene; FOXL2, forkhead box L2 gene; PTGER4, prostaglandin E receptor 4 gene; SHOX2, short stature homeobox 2 gene. Journal of Thoracic Oncology 2017 12, 77-84DOI: (10.1016/j.jtho.2016.08.123) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Receiver operating characteristic and area under the curve (AUC) analysis of pilot study 1 (AUC = 0.98) (A), study 2 (AUC = 0.91) (B), and study 3 (AUC = 0.95) (C). Journal of Thoracic Oncology 2017 12, 77-84DOI: (10.1016/j.jtho.2016.08.123) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Receiver operating characteristic and area under the curve (AUC) analysis of validation study: (A) Lung cancer (LC) versus all controls for training (AUC = 0.93) and validation study (AUC = 0.88), (B) LC versus nonmalignant disease (AUC = 0.86), (C) LC versus healthy controls (AUC = 0.91), (D) nonmalignant disease versus healthy controls (AUC = 0.58). Journal of Thoracic Oncology 2017 12, 77-84DOI: (10.1016/j.jtho.2016.08.123) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Comparison of protein (area under the curve [AUC] = 0.79) and methylation (AUC = 0.91) marker panel. The difference in the AUCs was statistically significant (p value = 0.004). Journal of Thoracic Oncology 2017 12, 77-84DOI: (10.1016/j.jtho.2016.08.123) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions